Abstract The BrainNet Europe consortium assessed the reproducibility in the assignment of the type of frontotemporal lobar degeneration (FTLD) with TAR DNA-binding protein (TDP) 43 following current recommendations. The agreement rates were influenced by the immunohistochemical (IHC) method and by the classification strategy followed. p62-IHC staining yielded good uniform quality of stains, but the most reliable results were obtained implementing specific Abs directed against the hallmark protein TDP43. Both assessment of the type and the extent of lesions were influenced by the Abs and by the quality of stain. Assessment of the extent of the lesions yielded poor results repeatedly; thus, the extent of pathology should not be used in diagnostic consensus criteria. Whilst 31 neuropathologists typed 30 FTLD-TDP cases, inter-rater agreement ranged from 19 to 100 per cent, being highest when applying phosphorylated TDP43/IHC. The agreement was highest when designating Type C or Type A/B. In contrast, there was a poor agreement when attempting to separate Type A or BrainNet Europe: http://www.brainnet-europe.org/.
Introduction
The neuropathological entity of frontotemporal lobar degeneration with transactivation responsive DNA-binding protein (TDP) 43-positive inclusions (FTLD-TDP) was recognised in 2006 . The lesions seen in FTLD-TDP were originally visualised with antibodies (Abs) directed against ubiquitin (Lowe et al. 1988; Jackson et al. 1996) or ubiquitin-binding protein p62/sequestosome (Arai et al. 2003; Pirici et al. 2006; Kuusisto et al. 2008; Pikkarainen et al. 2008) . Since 2006, Abs directed against TDP43 Arai et al. 2006; Davidson et al. 2007 ) and phosphorylated TDP43 (pTDP43) (Hasegawa et al. 2008; Neumann et al. 2009 ) have been used. Four histopathological subtypes of FTLD-TDP have been described, based on the predominant type, distribution and density of lesions (Mackenzie et al. 2006a, b; Sampathu et al. 2006; Cairns et al. 2007a, b) . In 2011, a harmonised classification system for FTLD-TDP pathology was proposed that was based on the previously published classification systems .
To date, immunohistochemical (IHC) methods applying various Abs, pretreatment strategies and detection systems have been utilised to visualise the hallmark lesions seen in FTLD-TDP. The type of lesions, their distribution and density form the basis for typing of the disorder (Mackenzie et al. 2006a Sampathu et al. 2006; Cairns et al. 2007a, b) . IHC methodology is prone to considerable variability that might cause differing results, as was elegantly reported by Mackenzie et al. (2006b) . Today, it is acknowledged that use of the IHC methods requires knowledge and competence both regarding methodology and interpretation of the result obtained (McNicol and Richmond 1998; Shi et al. 2001; Gelpi et al. 2007; D'Amico et al. 2009; Pikkarainen et al. 2010a ; Karlsson and Karlsson 2011; Kovacs et al. 2012 ). In addition, the agreement rate for the designation of a specific type of a disease by numerous investigators might be less optimal, as previously reported by BrainNet Europe (BNE) (Alafuzoff et al. 2008b (Alafuzoff et al. , 2009a .
The objectives of this BNE inter-laboratory study were to evaluate the quality of stains applied, reproducibility in the recognition of lesions and to assess the level of agreement in assigning histological types of FTLD-TDP.
Materials and methods
This study involved 18 BNE centres and a number of experienced neuropathologists. The study included two separate parts with four separate trials. In the first part of this study Production of sections 8 sets of sections were stained by applying optimised IHC methodology -ubiquitin, 1 set -p62 lck ligand, 3 sets -TDP43 monoclonal Ab, 2 sets -phosphorylated TDP43, 2 sets
The co-ordinating centre Sampling of the material Blocks of frontal cortex and hippocampus from 30 cases with FTLD-TDP pathology were obtained from four centres.
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TRIAL 1
Staining of a TMA section using screening IHC, antibodies directed to ubiquitin or p62. Assessment of the pathological immunoreactivity as instructed (Fig. 2) The participating neuropathologists
Assessment of eight sets of 30 stained cases
Each participant assessed the sections following the instructions given.
-ubiquitin, -p62 lck ligand, -TDP43 monoclonal Ab, -phosphorylated TDP43, Results of the assessments sent to the co-ordinator.
The co-ordinating centre
Summary of results
All results were filed and analysed.
All participants
Final decisions Pitfalls and difficulties were identified and conclusions were drawn.
TRIAL 2
Staining of a TMA section using recommended specific antibodies (TDP43) and methods Assessment of the pathological immunoreactivity as instructed (Fig. 2) 
TRIAL 3
Inter-rater assessment of the same TMA section stained with: -ubiquitin, -p62 lck ligand, -TDP43 polyclonal Ab, -TDP43 monoclonal Ab, -phosphorylated TDP43 Collection of routinely processed, paraffin embedded blocks of frontal cortex with FTLD-TDP pathology from the participating BNE centres Construction of tissue microarray (TMA) blocks for the assessments, cutting of 7-µm-thick TMAsections, evaluation of the comparability of TMAsections. Construction of assessment instructions and assessment sheets (Fig. 2 (Fig. 3) and construction of an assessment sheet (Supplement Fig. 1 ).
4
Subtyping of selected cases All sections stained were re-assessed jointly by the reference group under multi-headed microscope.
Each case was assigned a FTLD-TDP "type".
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The reference group A JOINT VIEWING, DISCUSSION AND DECISIONS Fig. 1 Flowchart summarising the structure of the study. The study is based on the work of 1 a defined co-ordinating group; 2 a reference group including neuropathologists working individually and jointly around a multi-headed microscope and 3 more than 20 participants working individually and participating at the joint viewing and discussions ( Fig. 1 left column) , methodological aspects were assessed including quality of staining and assignment of lesions, i.e., Trials 1-3. In the second part ( Fig. 1 right column) , agreement in stating the histopathological type of FTLD-TDP was assessed whilst applying current recommended classification strategies, i.e., Mackenzie et al. 2006a , b, Sampathu et al. 2006 or Cairns et al. 2007a Fig. 1 ). Each part included individual assessments carried out by participating neuropathologists followed by joint assessment around a multi-headed microscope. Both parts of the study followed the design previously described by BNE (Alafuzoff et al. , 2008a (Alafuzoff et al. , b, c, 2009a .
Part I: assessment of methodology
The tissue microarray (TMA) blocks were constructed as previously described from the blocks that were delivered to the co-ordinating centre (supplement Table 1 ) (Alafuzoff et al. , 2008a Kauppinen et al. 2006) . Prior to the distribution of the TMA sections to the participants, the uniformity/comparability of the sections, i.e., cores, was assessed by the co-ordinating centre as previously described (Alafuzoff et al. , 2008a . Briefly, the presence of p62 immunoreactive (IR) cytoplasmic inclusions and neurites was assessed in a set of TMA sections constructed for Trials 1 and 2. To facilitate the comparison of results, all cores with concomitant pathologies, i.e., hyperphosphorylated tau and/ or a-synuclein, were excluded. Furthermore, 15 representative core samples with variable TDP43-IR pathology were selected whilst summarising the final assessment results in Trials 1-3 (supplement Table 1 ).
BNE participant efforts
BNE participant efforts in Trials 1 and 2 as well as in Trial 3, i.e., inter-rater assessments, are summarised in Fig. 1 , left column. In brief, each BNE centre received one unstained section for each assessor, the protocol with recommended staining practices for Trial 2, assessment instructions including figures, and data sheets for recording of the assessments for Trials 1-3, wherein the assessment instructions and data sheets were the same for all three Trials (Fig. 2) .
In the first trial, the participants were asked to use a staining of their own choice, i.e., Abs directed against ubiquitin, p62 or TDP43 without strict methodological recommendations. Thereafter, obtained results were discussed at a joint meeting and subsequently, the Abs to be used in Trial 2 were agreed upon. Trial 3 was carried out after two joint assessments around a multi-headed microscope and several months after Trial 2. Eight to nine evaluators assessed the same TMA section of good/acceptable quality stained with ubiquitin, p62, monoclonal TDP43 (mono), polyclonal TDP43 (poly) or pTDP43-IHC. Briefly, here are the summary protocols with optimal results applied in Trial 3: ubiquitin MAB1510 Ab (clone Ubi-1, Chemicon, Temecula, CA, dilution 1:50,000, autoclave/120°C 10 min in aqua), p62 lck ligand (clone 3, BD Biosciences, Pharmingen, San Diego, CA 1:1,000, autoclave/120°C 10 min in citrate buffer pH 6.0), monoTDP43 (clone 2E2-D3, Abnova, Taipei, Taiwan, 1:300, autoclave/ 120°C 10 min in citrate buffer pH 6.0), polyTDP43 (10782-1-AP, Proteintech Group, Chicago, IL, 1:1,000, autoclave/ 120°C 10 min in aqua) and pTDP43 [rat mono Ab, clone 1D3 (Neumann et al. 2009 ), 1:50, autoclave/5 9 3 min in 10 mmol/L citrate buffer]. Figure 2 , panel 1, delineates the ubiquitin-, p62-or TDP43-IR structures that were to be assessed in a dichotomised manner (i.e., determination of the absence or presence) and semiquantitatively (Fig. 2, panel 2) in Trials 1-3.
Data analysis
The quality of staining in Trials 1 and 2 was evaluated from the whole sections stained by the participating BNE laboratories on a scale incorporating both staining intensity and background staining. The stainings were assessed as being of good quality when the staining clearly labelled the lesions evenly in most cores in a TMA section, as acceptable when lesions were detectable, but the intensity of staining between the cores varied with regard to the lesions and/or background, and as poor when the lesions were not detectable in some of the cores.
For dichotomised assessments, the percentage of positive (yes) assessment results for each Ab was calculated (Trials 1-3). For semiquantitative assessments, the range and the most frequent score were given (Trials 1-3). In addition, in Trial 3, participants were asked to state the density (Fig. 2 , panel 2) and predominant lesion in a given core (cytoplasmic inclusions or neurites).
Part II: designation of a subtype of FTLD-TDP Thirty cases from four centres were included. Regions selected were frontal cortex and hippocampus based on the current recommended assessment strategies (Mackenzie et al. 2006a; Sampathu et al. 2006; Cairns et al. 2007a, b) (supplement Fig. 1 ). All included cases displayed TDP43-IR lesions. A total of eight sets of 7-lm-thick sections were produced. There were 15 females (mean age at death 69 years) and 15 males (mean age at death 64 years); the mean age at death of the whole cohort was 67 ± SE 2 years (standard error of means).
Immunohistochemistry
Abs used included: ubiquitin (one set), p62 (three sets), mono TDP43 (two sets) and pTDP43 (two sets). All sets were manually stained applying IHC method optimised during Trial 3.
Reference assessment and construction of assessment instructions
The members of the reference group (IA, MN, TA, HK, MP) assessed all 30 cases in ubiquitin, p62, poly TDP43 and pTDP43 stains first individually and then jointly using a multi-headed microscope. The reference group assigned a FTLD-TDP subtype to each case (Mackenzie et al. 2006a Sampathu et al. 2006; Cairns et al. 2007a, b) when possible.
Assessment instructions were written by two members of the reference group (IA, MP). The instructions included a detailed description of the samples, general instructions regarding assessment and detailed tabulated guidelines for the subtyping (supplement Fig. 1 ). In addition, participants were urged to read the original publications (Mackenzie et al. 2006a; Sampathu et al. 2006; Cairns et al. 2007a, b) .
Inter-observer assessment
Twenty-six participants from 18 centres assessed and classified each case as instructed. Five participants assessed the cases that were stained applying ubiquitin, seven applying p62, eight applying poly TDP43 and six participants assessed the cases stained applying pTDP43. The results were recorded on the assessment sheets (supplement Fig. 2 ), which were sent to the co-ordinating centre. These assessment sheets included detailed observations of IR pathology in addition to the assigned types.
Consensus meeting and joint assessment
Following the phase of individual assessment, the group convened at a meeting to jointly assess the IHC-labelled sections around a multi-headed microscope. The diagnostic features of each type were discussed. Whilst assessing the stained sections under the multi-headed microscope, the actual observations were compared with the data recorded in the assessment sheets. Inconsistencies in these observations were discussed and pitfalls were sought.
Results
Part I: assessment of methodology
Trial 1
The co-ordinating centre received 30 stainings and 32 assessments from 17 BNE centres in Trial 1. Most of the received TMA sections (16) were stained with ubiquitin (12 stains with polyclonal and 4 with monoclonal Abs), nine were stained with p62 (1 stain with polyclonal and 8 stains with monoclonal Abs) and five were stained with TDP43 (3 stains with polyclonal and 2 stains with monoclonal Abs) (supplement Table 2 ).
The participants had used a variety of IHC methods that yielded variable staining quality from poor to good (supplement Table 2 ). In general, the intensity of IR structures, in particular neurites, varied notably between the different stainings. The intensity of IR also varied between the core samples within a TMA section in some of the stainings. When either polyclonal or monoclonal TDP43 Ab was used, the nuclei of cells were very intensively stained, which hindered the detection of lesions. Briefly, 56 % of the ubiquitin-stained sections (9 out of 16), all p62-stained sections and none of the TDP43-stained sections were of good/acceptable quality. Unless otherwise stated, results of Trial 1 given below include only assessments of slides having good/acceptable quality. Table 1 lists the results of the dichotomous (presence or absence) assessments using the ubiquitin and p62 Abs, i.e., screening Abs (supplement Table 3 ). In all 15 core samples that were assessed, there was 100 % agreement in the assessment of the presence of pathological ubiquitin-IR when compared with 93 % whilst applying p62. The agreement was not as good when assessing designated lesions, i.e., cytoplasmic inclusions and neurites. The agreement in assignment of thin respective thick neurites ranged from 33 to 53 % whilst applying ubiquitin, and from 33 to 73 % whilst applying p62 Abs. The most discrepant results were obtained when assessing intranuclear inclusions; the agreement was 33 % whilst applying ubiquitin and 40 % whilst applying p62 Ab.
The agreement in semiquantitative assessments of cytoplasmic inclusions or neurites was poor ranging from 13 to 33 % (Table 1, supplement Table 4) .
After a joint meeting during which the obtained staining results were viewed and discussed, a choice of method was agreed upon. The participants were asked to carry out stains for Trial 2, i.e., the participants were asked to follow prescribed staining instructions.
Trial 2
Fifteen BNE centres participated in Trial 2. Fourteen TMA sections were stained with p62 (2 stains with polyclonal and 12 with monoclonal Abs), and 11 were stained with TDP43 (9 stains with polyclonal and 2 stains with monoclonal Abs); thus, in total the co-ordinating centre received 25 assessments.
Even after harmonisation of the IHC methods, there was some variability in the methodology, most notably regarding the selection of heating methods and the time used for pretreatment (supplement Table 5 ). Furthermore, there was great variability in the selection of the detection systems. However, most of the received stainings were of good/acceptable quality (supplement Table 5 ). Briefly, 71 % of the p62-stained sections (10/14) and 82 % of TDP43-stained sections (9/11) were of good/acceptable quality.
Regarding the p62 Ab, the dichotomous and semiquantitative assessment results were comparable in Trials 1 and 2 (data not shown). Thus, results of the second trial below only include assessments of TDP43-stained slides of good/acceptable quality (Table 1) .
There was good to excellent agreement in the dichotomous assessment of IR with both the poly TDP43 and mono TDP43 (in 87 and 73 % of cores, respectively). In line with the previous Trial, the disagreement increased whilst assigning the lesions, i.e., cytoplasmic inclusions and neurites, ranging from 20 to 73 % whilst applying polyclonal and from 27 to 67 % whilst applying mono TDP43 (Table 1, supplement Table 6 ).
The agreement in the semiquantitative assessments of cytoplasmic inclusions or neurites was good in the majority of assessed core samples with the mono TDP43, whereas the agreement was poor with the poly Ab (Table 1, supplement Table 7) .
During a joint meeting, TMA sections produced by the participants during Trials 1 and 2 were assessed around a multi-headed microscope. Based on the obtained results, a set of TMA sections with optimal staining results were chosen for assessment in Trial 3. To disclose the influence of methodology, all participants were asked to assess the same cores in a TMA section stained with ubiquitin (8 assessors), p62 (8 assessors), TDP43 monoclonal (9 assessors), TDP43 polyclonal (8 assessors) and a newly produced TMA section stained applying pTDP43 (7 assessors). All stains were of good/excellent quality and the selected 15 cores represented all patterns of TDP43 pathology.
Trial 3
In total, the participants carried out 40 assessments. A good to excellent agreement, ranging from 87 to 100 %, was achieved in the dichotomous assessment of pathological IR, independent of the staining applied (Table 2, supplement Table 8 ). The Ab directed against the protein of interest seemed to perform better when compared with ubiquitin and p62, and the best results were obtained whilst applying the pTDP43. The separation of thick from thin neurites was still less optimal (73 vs 67 %).
The assessment of the density of IR structures is summarised in Table 3 . The most even assessments of the densities were achieved with the pTDP43. In 3 out of 15 cores, all evaluators had given the same density; moreover, in 10 out of 15 cores, most agreed with the assessment. The agreements in the densities were quite equal with p62, ubiquitin and polyclonal TDP43. The most variable assessments of the densities were obtained whilst assessing monoclonal TDP43-stained TMA.
The results of the predominance of IR structures (none, cytoplasmic inclusions, neurites or both) are provided in Table 4 . All evaluators had given the same assessment in 13 %/ubiquitin-, 13 %/p62-, 33 %/monoclonal TDP43-, 20 %/polyclonal TDP43-and 27 %/pTDP43-stained core samples.
Part II: designation of subtypes of FTLD-TDP
The members of the reference group (IA, MN, TA, HK, MP) agreed after the session around a multi-headed microscope that there were four cases that fulfilled the criteria for Type C , 11 fulfilled criteria for Type B; however, three were designated as being atypical, and nine cases fulfilled criteria for Type A.
It was impossible to differentiate between Type A and B in four cases; thus, these were designated as being mixed (A/ B). In two cases, the pathology was not sufficient to designate a subtype (Table 5) . No cases with Type D pathology were included.
Inter-observer assessment
Thirty-one participants from 18 centres classified the 30 included cases following the classification recommendations provided by Mackenzie et al. 2006a and Sampathu One stained tissue microarray section of good quality was selected to be assessed by all participants, i.e., inter-rater assessment Trial 3 Number of assessors is presented in parenthesis mono monoclonal, poly polyclonal, pTDP43 phosphorylated TDP43, excellent all assessors have seen or not seen immunoreactive (IR) lesions in the core sample; good agreement 85-99 % of assessors have seen or not seen IR lesions Table 3 Inter-rater assessments (Trial 3) of the density of pathological immunoreactive structures within the same core sample of a tissue microarray section stained with different commercial antibodies (15 core samples are included)
Core Density of immunoreactive structures
None Occ. to some 
Consensus meeting and joint assessment
Whilst jointly assessing the cases and discussing the obtained results, it was agreed that differentiation between Types A and B was difficult, independent of stain or classification systems used. In contrast, cases of Type C displaying prominent thick neurites were easily recognised and thus yielded good agreement results. After the joint meeting 26 participants typed by the reference group classified 28 cases following the Cairns et al. classification system from 2007a, b (Table 5) . Overall agreement was 66 % (ubiquitin-66 %, p62-61 %, monoclonal TDP43-73 % and pTDP43 68 %).
Discussion
Here, we assessed the reproducibility in the assignment of a type of FTLD-TDP whilst following current recommendations and noted that agreement rates were influenced by the IHC method, i.e., Abs applied, by the classification strategy followed (Mackenzie et al. 2006a; Sampathu et al. 2006) , by the subtype of FTLD-TDP and by training (Cairns et al. 2007a, b) . The IHC method applied included the screening Abs directed against ubiquitin, p62 and the specific Abs directed against TDP43 mono/poly and pTDP43. It is noteworthy that in addition to variability in the Abs, a wide range of pretreatment strategies and detection systems have been utilised. Previous methodological studies dealing with staining carried out on postmortem brain material have emphasised that the key factor for the quality of a staining is not only the Ab but also the antigen retrieval method (Alafuzoff et al. , 2008a Croisier et al. 2006) . When the participating laboratories followed their own IHC practices, the variations were remarkable particularly in ubiquitin stains (poor quality in 44 %). We noted that the same commercial ubiquitin-Ab yielded both good and poor results. For example, formic acid pretreatment abolished the staining, and a short incubation time at room temperature was deemed to be of poorer quality when compared with a longer incubation time at ?4°C. When a poly TDP43 or a mono TDP43 was used, nuclei were intensively stained with a strong stain, which interfered with the detection of lesions. The quality of TDP43 stains was improved when the participants received detailed instructions and it was noted that the p62-IHC staining, commonly used by all participants, yielded quite good uniform quality. Both poor and good results were produced independent of the mode of stain, i.e., manual vs automatic.
Both assessment of the type and the extent of lesions were influenced by the choice of Ab as well as by the quality of staining. In addition, we found that whilst assessing the same TMA core, the observers did indeed reach an absolute agreement whilst assessing the existence of pathological lesions. In contrast, there were some inconsistent results when the assessors were asked to identify specific lesions such as cytoplasmic inclusions or neurites. These results were improved in Trial 3 in comparison with Trials 1 and 2. In Trial 3, all investigators assessed the same cores in the same TMA section; thus, the differences due to staining quality were deleted. Moreover, Trial 3 followed two joint assessment sessions functioning as training sessions harmonising the interpretation of obtained IR. A general observation was that the assignment of lesions became more homogenous after the repeated trials and joint assessments around the multi-headed microscope, emphasising the need for similar sessions as part of training and not only for less experienced colleagues. The assessment of extent yielded, however, repeatedly poor results. Based on these observations, it became obvious that extent of pathology should not be used in diagnostic consensus criteria due to poor reproducibility in an inter-laboratory setting. This observation is in line with BNE's previous results whilst assessing interrater agreement in assessing a-synuclein pathology (Alafuzoff et al. 2009a).
The histological typing of FTLD-TDP includes semiquantitative assessments of cytoplasmic inclusions and/or intranuclear inclusions and neurites ranging from a few to numerous (Mackenzie et al. 2006a Sampathu et al. 2006; Cairns et al. 2007a, b) . Another significant variable to be taken into account is the predominant type of lesion (Mackenzie et al. 2006a Sampathu et al. 2006; Cairns et al. 2007a, b) . Moreover, the evaluation of the distribution (superficial vs transcortical) of pathology is emphasised in two of the typing schemes (Sampathu et al. Neuropathological assessments of the pathology 967
2006; Cairns et al. 2007a, b) . The observed results obtained here in Trials 1-3, whilst assessing methodological aspects, constitute a severe obstacle in the subtyping of FTLD-TDP. All parameters to be assessed are highly dependent on the staining quality obtained. Of note, the classification strategion, i.e., Mackenzie et al. (2006a) and Sampathu et al. (2006) , were originally designed whilst applying screenings antibody Ubq. These instructions have then been applied whilst using other antibodies such as p62, mono/poly TDP43 and pTDP43. Each of the antibodies tends to stain different lesions in various extents and this might in addition influence the outcome whilst assigning a type of FTLD-TDP and using different antibodies.
Here, we noted that whilst 31 assessors stated the type of FTLD-TDP, the agreement with the reference group ranged from 19 to 100 %. In particular, the highest agreement was obtained whilst assessing lesions visualised with specific Abs (TDP43 and pTDP43) when compared with the screening Abs (Ubq, p62). The significance of the IHC method was emphasised in a recent report indicating that the use of phosphorylated when compared with nonphosphorylated TDP43 resulted in a higher inter-observer agreement variation when five experienced neuropathologists classified 14 FTLD cases into subtypes (Tan et al. 2013) . Furthermore, it was noted that when the classification strategy required the distribution of pathology in addition to the assessment of type of lesion, the results were poorer when compared with classification strategy primarily based on the type of pathology (Mackenzie et al. 2006a performed better when compared with Sampathu et al. 2006) . It was apparent that classification of a type with clearly identifiable lesions such as long neurites (Type C) yielded higher agreement when compared with types that were quite similar (Types A and B), i.e., many/moderate neuronal cytoplasmic inclusions with many/few neurites. The visualisation of the latter pathology, i.e., neurites, is highly dependent on the staining quality. In cases that were not discernable (mixed Type A/B), the agreement rate whilst applying specific antibody (TDP43) and following type-oriented classification strategy (Mackenzie et al. 2006a was also acceptable.
Whilst jointly assessing the cases, it was noted that in most of them the pathology was distributed throughout the entire thickness of the cortex; subsequently, it was difficult to agree on the predominant distributional pattern of pathology even around the multi-headed microscope. Thus, it is impossible to strictly follow the given instructions, including statements such as infrequent neurites in deep and superficial cortical layers in Type B, and predominance of small neurites and inclusions in superficial cortical layer in Type A. This might partly explain the poor agreement observed here whilst assigning Type A or B cases. What is reported here is probably not exceptional but rather the rule, i.e., whilst classifying cases into Types A and B, the results might depend on the variability in the staining quality (influencing the extent and type of pathology that can be seen). Furthermore, one should not rule out the significant influence of ''experience'', i.e., assessing one FTLD-TDP case/year vs assessing one FTLD-TDP case/ month. Some influence on agreement results was noted after the joint meeting when the classification systems were discussed (38 % agreement when following Sampathu et al. 2006 when compared with 66 % agreement when following Cairns et al. 2007a, b) . The difficulty in reaching high agreement rates in the inter-laboratory setting was also emphasised in previous BNE publications, indicating that even with respect to common pathologies such as Alzheimer's disease (AD)-related lesions or a-synuclein pathology, full agreement is not reached by experienced neuropathologists even though very detailed instructions are available (Alafuzoff et al. 2008b (Alafuzoff et al. , 2009a .
Results obtained here are in principle in line with the results obtained previously by BNE consortium. It has previously been reported that choice of Ab and use of methodology are of significant importance. The community should be aware of the multitude of issues that influence the staining outcome (fixative, fixation time, storage time of sections) and that this influence varies from one epitope to another (McNicol and Richmond 1998; Shi et al. 2001; Gelpi et al. 2007; D'Amico et al. 2009; Pikkarainen et al. 2010a; Karlsson and Karlsson 2011; Kovacs et al. 2012) . Another issue that the BNE consortium has become aware of is the need for precise detailed instructions. In all previous trials, it became obvious that the main factor influencing the outcome of ''staging'' or ''typing'' a given pathology was the neuroanatomical distribution of pathology. Thus, regarding classification of FTLD-TDP cases lacking as yet discernable neuroanatomical progression pattern of pathology, one should probably primarily assess whether TDP43 pathology is or is not seen (TDP43-IR inclusions and neurites), leading to a diagnosis of FTLD-TDP. Subsequently, if many long neurites are seen, then Type C could be designated. Types A and B are not fully discernable based on our results and thus when not convinced about the type, Type A/B (mixed) should be assigned.
Recent reports suggest that in line with other neurodegenerative diseases a staging of TDP43 pathology based on sequential regional distribution can be carried out (Brettschneider et al. 2013 (Brettschneider et al. , 2014 Josephs et al. 2014) . A stepwise neuroanatomical progression pattern has been identified in behavioural variant of FTLD-TDP with regions such as orbital gyrus and amygdala primarily involved, in amyotrophic lateral sclerosis (ALS) with agranular motor cortex and medulla oblongata at the level of nerve XII primarily involved and in AD with amygdala and entorhinal cortex primarily involved (Brettschneider et al. 2013 (Brettschneider et al. , 2014 Josephs et al. 2014) . Based on our observations and the recent reports suggesting a sequential evolvement of pathology, TDP43 pathology should probably initially be assessed in at least three regions, i.e., amygdala, hippocampus and medulla oblongata as observed or not seen (TDP43-IR inclusions and neurites), leading to verification of existing FTLD-TDP pathology. Subsequently in a case of ALS, behavioural variant of FTLD-TDP or AD additional neuroanatomical regions should be assessed as recently recommended (Brettschneider et al. 2013 (Brettschneider et al. , 2014 Josephs et al. 2014) . Furthermore, regarding FTLD-TDP, if many long neurites are seen, then Type C could be designated. Types A and B are not fully discernable based on our results and thus when not convinced regarding the type, Type A/B (mixed) should be assigned. Furthermore, p62 pathology in the cerebellar cortex should be investigated on all Types of FTLD-TDP cases to identify subjects with C9orf72 repeat expansion (Fig. 3) (Cairns et al. 2007a, b; Pikkarainen et al. 2008 Pikkarainen et al. , 2010b Pikkarainen et al. , 2011 Mahoney et al. 2012) . In addition when the subjects display familial clustering appropriate On all cases with clinical signs of a neurodegenerative disease, a TAR DNA binding protein (TDP)43 stain should be carried out on the hippocampal slide, amygdala and medulla at the level of nerve XII. (Brettschneider et al 2013 , Josephs et al. 2014 . Note immunoreactive cytoplasmic inclusions in agranular cell layer, in b-entorhinal cortex and in c-amygdala. Magnification x400.
If TDP43 immunoreactivity is noted in the amygdala, hypoglossus or hippocampus, TDP43 stain should be carried out on additional section including frontal cortex (Brettschneider et al 2013 , Josephs et al. 2014 . The selection of neuroanatomical regions to be assessed is influenced by the primary disease, i.e., Frontotemporal dementia, Amyotrophic Lateral Sclerosis or Alzheimer's disease d-note immunoreactive cytoplasmic inclusions in frontal cortex. Magnification x400.
When assessing TDP43 pathology in frontal cortex, state the type of FTLD-TDP, i.e. type A,B,C or type D following recent recommendations . If differentiation between the types is troublesome state the mixture of pathologies seen A/B, A/C or B/C, Carry out p62 lck ligand stain on cerebellar cortex (e-note cytoplasmic inclusions in magnification x400). Magnification x400
Carry out assessment of Alzheimer's disease related pathology as previously recommended by BrainNet Europe and the National Institute on Aging-Alzheimer's Association (Alafuzoff et al. , 2009 Hyman et al. 2012; Montine et al. 2012) genetic assessment should be carried out and thus sampling of frozen tissue should always be done.
In conclusion, in line with previous BNE studies, there are limitations to reaching broad consensus in inter-laboratory settings. It is possible to achieve staining results of high quality and also some level of agreement regarding the interpretation of staining results. Currently, we can expect that neuropathologists, independent of their familiarity with FTLD-TDP pathology, can identify a TDP43-positive FTLD case. Some agreement can be reached regarding Type C with thick and long neurites, whereas the differentiation between Types A and B may be troublesome. This should be kept in mind, since different FTLD-TDP types are reported to be associated with a particular genotype and/or clinical phenotype, e.g., semantic dementia being associated with Type C, progranulin mutations or aphasia with Type A, and FTLD-TDP with motor neuron disease and linkage to chromosome 9 would correspond with Type B (Josephs et al. 2011 ). C9orf72 repeat expansion has been described in other than Type B cases and thus, p62 pathology in cerebellar cortex should be assessed in all FTLD-TDP cases. In general neuropathologists are urged to state defined types of FTLD (A, B, C, D and mixed A/B, A/C, B/C); however, one should be aware that the given type by one neuropathologist might not be in agreement with the type given by another neuropathologist. Recent reports describing a sequential neuroanatomical evolvement of TDP43 pathology in behavioral variant of FTLD-TDP, ALS and AD will certainly influence the future agreement rates (Brettschneider et al. 2013 (Brettschneider et al. , 2014 Josephs et al. 2014) . It has previously been reported by BNE that dichotomized assessment of pathology in defined neuroanatomical regions disregarding the extent of lesions tends to yield good agreement rates in inter-laboratory setting (Alafuzoff et al. 2008b (Alafuzoff et al. , 2009a . The use of digital pathology facilitating viewing of representative cases in addition to reading instructions might with time harmonise the typing and staging of more unusual pathologies. Noteworthy, assessment of TDP43 immunoreactivity is not only of significance in FTLD-TDP. TDP-43 pathology when observed in amygdala has been reported to be of significance whilst estimating clinical features in subjects with 23 Alzheimer's disease (Josephs et al. 2014 ). In Fig. 3 , a flowchart is given summarising the general handling of a case with neurodegenerative diseases with respect to TDP43 pathology.
